Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices

BACKGROUND All established disease-modifying drugs for multiple sclerosis require parenteral administration, which can cause difficulties for some patients, sometimes leading to suboptimal adherence. A new electronic autoinjection device has been designed to address these issues. METHODS Patients with relapsing multiple sclerosis currently receiving subcutaneous or intramuscular interferon beta-1a, interferon beta-1b, or glatiramer acetate completed an online questionnaire (July 4-25, 2008) that surveyed current injection practices, experiences with current injection methods, and impressions and appeal of the new device. RESULTS In total, 422 patients completed the survey, of whom 44% used autoinjectors, 43% prefilled syringes, and 13% syringes and vials; overall, 66% currently self-injected. Physical and psychological barriers to self-injection included difficulty with injections, needle phobia, and concerns over correct injection technique. Only 40% of respondents were "very satisfied" with their current injection method. The new electronic autoinjector was rated as "very appealing" by 65% of patients. The benefits of the new device included the ability to customize injection settings and to review dosing history. CONCLUSION New technologies may help patients overcome physical and psychological barriers to self-injection. The combination of a reliable and flexible autoinjection device with dose-monitoring technology may improve communication between health care professionals and patients, and improve treatment adherence.